[1] FRANCIS K. MAINA Tiffany A M. Functional Fast Scan Cyclic Voltammetry Assay to Characterize Dopamine D2 and D3 Autoreceptors in the Mouse Striatum[J]. ACS Chemical Neuroscience, 2010, 1 6: 450-462. DOI:
10.1021/cn100003u[2] RICHARD E. MEWSHAW. New Generation Dopaminergic Agents. 1. Discovery of a Novel Scaffold Which Embraces the D2 Agonist Pharmacophore. StructureActivity Relationships of a Series of 2-(Aminomethyl)chromans[J]. Journal of Medicinal Chemistry, 1997, 40 26: 4235-4256. DOI:
10.1021/jm9703653[3] G S ROBERTSON. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release.[J]. Journal of Pharmacology and Experimental Therapeutics, 1993, 264 3: 1344-1351.
[4] KITAMURA Y. [Dopaminergic neuroprotection and reconstruction of neural network tiara].[J]. Yakugaku zasshi: Journal of the Pharmaceutical Society of Japan, 2010, 130 10: 1263-1272. DOI:
10.1248/yakushi.130.1263[5] HIROAKI NISHIO . 5-HT3 receptor blocking properties of the antiparkinsonian agent, talipexole[J]. General Pharmacology-the Vascular System, 1996, 27 5: Pages 779-785. DOI:
10.1016/0306-3623(95)02125-6[6] DANIEL RICCI Carlos A T. Adrenoceptor Involvement in the Cardiovascular Responses to B-HT 920 in Sinoaortic Denervated Rats[J]. General Pharmacology-the Vascular System, 1999, 32 1: Pages 29-34. DOI:
10.1016/s0306-3623(98)00018-4
